GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (STU:AT2) » Definitions » Total Liabilities

Atara Biotherapeutics (STU:AT2) Total Liabilities : €242.49 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Atara Biotherapeutics Total Liabilities?

Atara Biotherapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was €242.49 Mil.

Atara Biotherapeutics's quarterly Total Liabilities increased from Sep. 2023 (€224.53 Mil) to Dec. 2023 (€242.76 Mil) but then declined from Dec. 2023 (€242.76 Mil) to Mar. 2024 (€242.49 Mil).

Atara Biotherapeutics's annual Total Liabilities increased from Dec. 2021 (€166.83 Mil) to Dec. 2022 (€235.79 Mil) and increased from Dec. 2022 (€235.79 Mil) to Dec. 2023 (€242.76 Mil).


Atara Biotherapeutics Total Liabilities Historical Data

The historical data trend for Atara Biotherapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Total Liabilities Chart

Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.95 103.39 166.83 235.79 242.76

Atara Biotherapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 221.47 220.58 224.53 242.76 242.49

Atara Biotherapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Atara Biotherapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=130.421+(41.9+35.997
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+34.444+0)
=242.76

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=151.767--90.995
=242.76

Atara Biotherapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=166.235+(38.821+36.777
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.661+0)
=242.49

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=152.05--90.443
=242.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atara Biotherapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (STU:AT2) Business Description

Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (STU:AT2) Headlines

No Headlines